PBAC's latest decision on Alogliptin with metformin: Recommended with restriction (2013). Considered for Type 2 diabetes mellitus in patients whose HbA1c is greater than 7% despite treatment with metformin, without requiring prior intolerance or contraindication to metformin and sulfonylurea combination.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2013
Submissions
1
2013 → 2013
Eligible population
Adult patients (≥18 years) with type 2 diabetes mellitus whose HbA1c is greater than 7% despite treatment with metformin alone, where a dipeptidyl peptidase 4 inhibitor is appropriate, and where metformin and sulfonylurea combination is contraindicated or not tolerated.
Therapy area
Endocrinology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
Surrogate
Pivotal trial size
5,380 patients
Key trials
MET-103, MET-101, 322-101, MET-302
Comparator
alogliptin plus metformin individual tablets
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design